Skip to Content

Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets

PITTSBURGH, March 26, 2007 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced its latest first to market generic product with the launch of Ciprofloxacin Extended-release (ER) Tablets in 500mg and 1000mg strengths. Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for both strengths of Ciprofloxacin ER Tablets on Thursday, March 22 and began shipping immediately that day. Ciprofloxacin ER is the latest Mylan generic product that leverages Mylan's expertise in extended release formulations.

Ciprofloxacin ER Tablets are the generic version of Bayer Pharmaceuticals' Cipro(R) XR Tablets, which had U.S. sales of approximately $45 million for the same strengths for the 12-month period ending Dec. 31, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit

CONTACT: Patrick Fitzgerald, or Kris King, +1-724-514-1800

Web site:

Ticker Symbol: (NYSE:MYL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2007